How Far Has AM in Healthcare Really Come? Find Out at RAPID + TCT 2026

Why It Matters

These developments signal that AM is becoming a viable, regulated pathway for mass‑producing customized medical products, reshaping supply chains and accelerating personalized therapies. The insights shared will guide manufacturers, regulators, and clinicians toward faster, safer market adoption.

Key Takeaways

• Standardizing processes enables scalable personalized orthotics
• FDA requires traceable documentation for each AM device
• OEM partnerships bridge speed with regulatory compliance
• Bioprinted myeloma models improve personalized treatment decisions
• RAPID+TCT accelerates collaboration and technology maturation

Pulse Analysis

Additive manufacturing has long promised bespoke medical solutions, but the real test lies in moving from lab prototypes to regulated production. At RAPID + TCT 2026, industry leaders demonstrated that the missing link is not technology alone but disciplined process control. By treating personalization as a default element within a tightly standardized workflow, companies like iOrthotics can deliver orthotics that match individual biomechanics while maintaining repeatable quality—a model that could be replicated across other patient‑specific devices.

Regulatory compliance remains the biggest hurdle for AM‑based medical devices. The FDA’s expectation for detailed, traceable documentation forces manufacturers to rethink the rapid‑iteration culture typical of 3‑D printing. Experts such as Laura Gilmour highlighted that successful OEM collaborations hinge on embedding risk‑management and documentation practices early in the design phase. This partnership approach balances the speed of additive processes with the rigor required for FDA clearance, paving the way for broader adoption across high‑risk device categories.

Bioprinting is pushing the frontier further by creating living tissue models that mirror individual disease phenotypes. Julio Aleman's work on patient‑specific multiple myeloma constructs showcases how reproducible, human‑derived bio‑inks can generate accurate drug‑response platforms, reducing reliance on animal testing and accelerating personalized oncology. Coupled with the FDA’s emerging NAMs Framework, these advances suggest a near‑term transition from experimental labs to routine clinical decision‑making, positioning AM as a cornerstone of next‑generation healthcare delivery.